Investor Updates

December 23, 2011
Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer
Roche announced today that the European Commission has approved Avastin (bevacizumab) in combination with standard chemotherapy ... more

December 16, 2011
Roche's personalized medicine Zelboraf receives positive opinion from European authority for the treatment of people with BRAF mutation-positive metastatic melanoma
Roche, today announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended that Zelboraf be granted ... more

December 12, 2011
First head to head study shows higher response rates for GA101 vs. MabThera/Rituxan without appreciable differences in safety in common type of blood cancer
Separate study indicates that GA101 is highly effective in combination with chemotherapy. Roche announced today that its investigational ... more

December 08, 2011
Reminder: Roche conference call for investors and analysts from SABCS 2011
CLEOPATRA, a phase III trial of pertuzumab plus trastuzumab plus docetaxel in first-line treatment of patients with HER2-positive ... more

December 08, 2011
Roche announces positive results of pivotal Phase III study with pertuzumab in HER2-positive metastatic breast cancer
Roche today announced results from CLEOPATRA, the first randomised Phase III study of the investigational HER2-targeted medicine ... more

December 01, 2011
Roche’s cobas EGFR Mutation Test For Personalized Treatment Of Non-Small Cell Lung Cancer Receives CE Mark
New Test allows identification of lung cancer patients who may benefit from early treatment with EGFR inhibitors. Roche announced ... more

November 30, 2011
Roche conference call for investors and analysts from SABCS 2011
CLEOPATRA, a phase III trial of pertuzumab plus trastuzumab plus docetaxel in first-line treatment of patients with HER2-positive ... more

November 30, 2011
Roche to present important new data for HER2-positive breast cancer at 2011 San Antonio Breast Cancer Symposium
Roche today announced that it will present results from studies of its investigational medicine pertuzumab in HER2-positive ... more

November 23, 2011
Roche purchases shares in tender offer for Anadys Pharmaceuticals
Roche today announced that its wholly owned subsidiary Bryce Acquisition Corporation has accepted for payment all shares validly ... more

November 18, 2011
FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer
U.S. Food and Drug Administration (FDA) Commissioner revokes approval of Avastin for treatment of metastatic breast cancer ... more

November 09, 2011
FDA accepts Roche's New Drug Application for vismodegib in advanced form of skin cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed the company’s New Drug ... more

October 31, 2011
Reminder: Invitation to Late-stage pipeline event Monday, 7 November 2011
The Roche Investor Relations team would like to invite you to a Late-stage pipeline event that will take place in London on ... more

October 20, 2011
Phase II study showed ocrelizumab maintained significant reduction in disease activity for multiple sclerosis patients for almost two years
Phase III trials underway to investigate ocrelizumab in two forms of MS. Roche today announced 96-week results from a Phase ... more

October 18, 2011
Roche reports positive study of Herceptin given by subcutaneous injection
Phase III study of a quicker route of administration shows comparable results to intravenous Herceptin. Roche today announced ... more

October 17, 2011
Roche signs definitive agreement to acquire Anadys Pharmaceuticals
Roche and Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) today announced that the two companies have entered into a definitive ... more

October 13, 2011
Roche posts solid sales performance in first nine months, achieves significant progress with personalised healthcare approaches
Group sales rise 2% at CER (-12% in Swiss francs; +7% in US dollars), excluding Tamiflu; Significant foreign exchange impact ... more

October 11, 2011
Invitation to Late-stage pipeline event Monday, 7 November 2011
The Roche Investor Relations team would like to invite you to a Late-stage pipeline event that will take place in London on ... more

October 06, 2011
Reminder: Invitation to Roche's Third Quarter Sales 2011 Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday ... more

September 30, 2011
Roche wins first major public tender in Europe to screen women for cervical cancer with its Human Papillomavirus test
Roche announced today that it has been awarded an exclusive contract by Karolinska University Hospital in Stockholm, Sweden, ... more

September 29, 2011
Roche receives clearance from the U.S. Food and Drug Administration for new generation of Accu-Chek Aviva Plus Test Strips for people with diabetes
Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Accu-Chek Aviva ... more

September 26, 2011
Peginterferon alfa-2a “Pegasys” Approved for Additional Indication of “Chronic Active Hepatitis B”
Please find attached a press release by Chugai more

September 26, 2011
Anti-Cancer Agent, Avastin Obtained Approval for Additional Indication and Dosage and Administration of “Inoperable or Recurrent Breast Cancer“
Please find attached a press release by Chugai. more

September 25, 2011
Roche's investigational medicine T-DM1 shows improvement in progression-free survival compared to standard of care in HER2-positive metastatic breast cancer
Roche today announced the results of the Phase II study TDM4450g in patients with previously untreated HER2-positive metastatic ... more

September 24, 2011
Avastin and pemetrexed combination gives lung cancer patients significantly more time without their disease progressing
Roche today announced that AVAPERL, a phase III study evaluating the combination of Avastin® (bevacizumab) and chemotherapy ... more

September 23, 2011
Roche's Avastin receives positive opinion from European authority for the treatment of women with newly diagnosed advanced ovarian cancer
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the ... more

September 19, 2011
Roche highlights data that demonstrate a range of new approaches to target breast, skin and lung cancers at 2011 European Multidisciplinary Cancer Congress
Roche today announced that encouraging data on its investigational and approved medicines will be presented at the 2011 European ... more

September 14, 2011
Invitation to Roche's Third Quarter Sales 2011 Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday ... more

September 13, 2011
Reminder Investor Day: Roche Diagnostics Enabling Personalised Healthcare
We are pleased to invite you to our Roche Diagnostics Investor Day on 21 September at 14:30 BST / 15:30 CET / 9:30 AM EDT ... more

September 08, 2011
Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year
Reinforces commitment to creating long-term value for all stakeholders. Roche announced today that it has been recognized ... more

September 02, 2011
Chugai Initiates Clinical Trials for Multiple In-Licensed Compounds
Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, “Chugai”)] ... more

September 01, 2011
Roche's Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer
Personalised Healthcare strategy allows to identify lung cancer patients who benefit from early treatment with Tarceva. Roche ... more

August 29, 2011
Dalcetrapib phase II studies support the safety profile and potential for slowing of plaque progression in patients at risk of coronary heart disease
Roche announced today results from two exploratory mechanistic Phase IIb studies investigating dalcetrapib’s effects ... more

August 25, 2011
Roche Investor Science Call from ESC 2011: Phase II data from the endothelial function study dal-VESSEL and the imaging study dal-PLAQUE
We kindly invite investors and analysts to participate in a conference call that will be held during the European Society ... more

August 22, 2011
Investor Day: Roche Diagnostics Enabling Personalised Healthcare
We are pleased to invite you to our Roche Diagnostics Investor Day on 21 September at 14:30 BST / 15:30 CET / 9:30 AM EDT ... more

August 17, 2011
FDA approves Zelboraf (vemurafenib) and companion diagnostic for BRAF mutation-positive metastatic melanoma, a deadly form of skin cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of ... more

August 15, 2011
Roche Investor Science Event from ESC 2011
Phase II data from the endothelial function study dal-VESSEL and the imaging study dal-PLAQUE - Monday, 29 August 2011, Paris, ... more

August 15, 2011
Chugai to In-license BRAF Inhibitor Vemurafenib
Dear Investor, Please find attached a press release by Chugai. more

August 04, 2011
Roche's investigational treatment for asthma met its primary endpoint in a phase II study
Roche today announced that a phase II study of its investigational treatment lebrikizumab, a humanized monoclonal antibody ... more

August 03, 2011
Roche’s RoACTEMRA approved in Europe for children living with a rare and severe form of arthritis
Medicine offers new treatment option for Systemic Juvenile Idiopathic Arthritis (sJIA). Roche announced today that the European ... more

July 22, 2011
Roche's Tarceva gains positive CHMP opinion for first-line use in genetically distinct type of lung cancer
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in the ... more

July 22, 2011
Full reconciliation of Chugai interim results into IFRS
Results of Chugai as consolidated by the Roche Group. Following the publication of Chugai’s official 2011 interim results, ... more

July 21, 2011
Roche on track - full year earnings outlook increased
Group sales stable in local currencies. Excluding Tamiflu, Group sales up 2% and Pharmaceuticals Division sales up 1%; Diagnostics ... more

July 19, 2011
Anti-Human IL-6 Receptor Monoclonal Antibody "Actemra" Subcutaneous Injection Demonstrates Efficacy in Rheumatoid Arthritis in Phase III Clinical Study
Dear Investor, please find attached a press release by Chugai. Do not hesitate to contact us for any further questions. more

July 19, 2011
Roche acquires mtm laboratories AG, expanding offering in cervical cancer testing
Roche announced today that it has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), ... more

July 15, 2011
Pertuzumab combined with Herceptin and chemotherapy significantly extended the time people with HER2-positive metastatic breast cancer lived without their disease getting worse
Roche today announced that CLEOPATRA, a pivotal Phase III study, met its primary endpoint. more

July 14, 2011
Reminder: Invitation to Roche's Half Year Results for 2011
Roche will publish its Half Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 21st July at 7:00 CET ... more

July 14, 2011
Roche researchers develop antibody that crosses the blood-brain barrier more efficiently
Roche announced today two research publications from its Early Development unit gRED outlining how a new technology successfully ... more

July 01, 2011
Anti-Cancer Agent, Tarceva Obtained Approval for Additional Indication of Pancreatic Cancer Not Amenable to Curative Resection and Measures for Proper Use
Dear Investor, please find attached a press release by Chugai. Do not hesitate to contact us for any further questions. more

July 01, 2011
Chronic Hepatitis C Treatment, Pegasys, and Antiviral Drug, Copegus, Obtained Approval for Additional Indication of Compensated Liver Cirrhosis Related to Hepatitis C
Dear Investor, please find attached a press release by Chugai. Do not hesitate to contact us for any further questions. more

June 30, 2011
Roche's Avastin receives broader EU label for women with metastatic breast cancer
Expanded label allows combination with Xeloda or paclitaxel in first-line setting. Roche announced today that the European ... more

June 30, 2011
Roche provides update from FDA hearing on Avastin for metastatic breast cancer
FDA Commissioner to Make Final Decision at a Later Date. Roche announced today that, during a U.S. Food and Drug Administration ... more

June 29, 2011
Two pivotal phase III Lucentis studies showed patients with diabetic macular edema experienced significant improvements in vision and fewer developed more advanced retinopathy
Two-Year Data from RISE and RIDE studies presented at the American Diabetes Association Annual Scientific Sessions. Genentech, ... more

June 24, 2011
Invitation to Roche's Half Year Results for 2011
Roche will publish its Half Year Results for 2011 prior to the opening of the Swiss Stock Exchange on 21st July at 7:00 CET ... more

June 20, 2011
Pivotal study showed vismodegib helped shrink tumours or heal lesions in people with rare form of advanced skin cancer
Roche announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal ... more

June 05, 2011
Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations
Roche’s Personalised Healthcare approach demonstrated through vemurafenib and its investigational companion diagnostic, ... more

June 04, 2011
Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer
Phase III OCEANS results add to the growing body of evidence supporting Avastin’s potential role in ovarian cancer. ... more

June 03, 2011
Tarceva nearly doubled the time people with a genetically distinct type of lung cancer lived without their disease getting worse
Roche today announced results of EURTAC, the first Phase III study with Tarceva (erlotinib) in Western patients with a genetically ... more

June 02, 2011
Roche enters collaboration with Bristol-Myers Squibb to study combination therapy with vemurafenib and ipilimumab in advanced skin cancer
Roche today announced that it has entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY) ... more

May 27, 2011
Roche Analyst Event at ASCO 2011
Analyst briefing on data presented at ASCO: Sunday, 5th June 2011. We are pleased to invite you to an analyst briefing to ... more

May 26, 2011
RoACTEMRA could change the current standard of treatment for people living with rheumatoid arthritis
New study confirms RoACTEMRA is effective when used on its own for people who do not respond to methotrexate. Roche today ... more

May 20, 2011
RoActemra offers a new option for children living with a rare and severe form of arthritis
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an ... more

May 20, 2011
Roche ASCO Planner
Roche and Genentech will present a large number of abstracts on their broad oncology portfolio at the American Society of ... more

May 19, 2011
MetMAb in combination with Tarceva doubled the time people with lung cancer lived without their disease getting worse
Roche today announced final results from a randomised, multicentre, double-blind Phase II study with its investigational personalised ... more

May 18, 2011
Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO
Progress in advanced skin and lung cancers through personalised healthcare. New Phase III data for Avastin in ovarian cancer ... more

May 17, 2011
Roche and Merck Establish Strategic Agreements in Fight Against Chronic Hepatitis C
Roche announced today that it has entered into agreements with Merck, known as MSD outside the United States, through their ... more

May 11, 2011
New drug applications submitted in the United States and Europe for vemurafenib in advanced skin cancer
Roche today announced that the company submitted a New Drug Application for vemurafenib (RG7204, PLX4032) to the U.S. Food ... more

May 05, 2011
Roche Analyst Event at ASCO 2011
Analyst briefing on data presented at ASCO: Sunday, 5 June 2011 We are pleased to invite you to an analyst briefing to discuss ... more

April 26, 2011
Long-Acting Erythropoiesis Stimulating Agent, Mircera Injection Syringe, approved in Japan
Press release by Chugai more

April 20, 2011
FDA approves Rituxan/MabThera plus a steroid for use in severe forms of vasculitis
Roche and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab), ... more

April 20, 2011
FDA Approves Roche’s HPV Test for Identifying Women at Highest Risk for Cervical Cancer
Roche announced today that the US Food and Drug Administration (FDA) has approved the cobas HPV (Human Papillomavirus) Test ... more

April 19, 2011
Diversity of approaches in research continues to empower scientific excellence at Roche
Roche announced today that the Group's strong scientific publication track record from Genentech's and Roche's ... more

April 18, 2011
FDA approves Actemra for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)
Medicine offers a new option for children living with a rare and severe form of arthritis. Roche today announced that the ... more

April 15, 2011
Roche gains positive CHMP opinion for the combination of Avastin with Xeloda as a first-line treatment for metastatic breast cancer in Europe
Approval would allow combination of Avastin with paclitaxel or Xeloda, offering more choice to physicians and patients. Roche ... more

April 14, 2011
Roche Group's first-quarter 2011 sales on track for full-year targets - positive results in seven key clinical trials
Group sales stable in local currencies (-9% in Swiss francs; +2% in US dollars) at 11.1 billion Swiss francs in first three ... more

April 07, 2011
Reminder: Invitation to Roche's First Quarter Sales 2011 Conference Call - Thursday April 14th, 2011
Roche will publish its Sales Results for the 1st Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday ... more

April 07, 2011
Roche announces positive Phase II results for trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer
Roche today announced topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic ... more

April 01, 2011
Dalcetrapib Phase II studies dal-VESSEL and dal-PLAQUE show encouraging results
Roche announced today that the results from two exploratory Phase IIb studies, dal-VESSEL and dal-PLAQUE, further support ... more

March 28, 2011
Second Lucentis Phase III study meets primary endpoint for improved vision in patients with diabetic macular edema (DME)
Results consistent with data released last month showing patients with DME who received Lucentis achieved significant improvement ... more

March 21, 2011
Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor in advanced basal cell carcinoma
Roche today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib ... more

March 15, 2011
Invitation to Roche's First Quarter Sales 2011 Conference Call - Thursday April 14th, 2011
Roche will publish its Sales Results for the 1st Quarter of 2011 prior to the opening of the Swiss Stock Exchange on Thursday ... more

March 15, 2011
Roche acquires PVT to strengthen laboratory automation in clinical diagnostics
Roche announced today the acquisition of PVT Probenverteiltechnik GmbH based in Waiblingen, Germany and of PVT Lab Systems, ... more

March 10, 2011
Phase III study of Lucentis showed rapid vision improvements sustained for two years in patients with diabetic macular edema
Roche today announced that two-year results from a pivotal Phase III trial (RISE) showed patients with diabetic macular edema ... more

March 10, 2011
Herceptin approved in Japan for additional indication of advanced or recurrent gastric cancer overexpressing HER2, which is not amenable to curative resection
more

March 02, 2011
European Commission continues to support Avastin in combination with paclitaxel as an effective treatment option for women with metastatic breast cancer
Roche announced today that the European Commission confirmed that Avastin (bevacizumab) in combination with paclitaxel will ... more

March 01, 2011
Roche Annual General Meeting: dividend raised by 10%
Roche's Annual General Meeting, which was held today in Basel, has approved all of the Board of Directors' proposals. ... more

February 25, 2011
Pivotal Study Validates Roche’s cobas HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer
Roche announced that a study published online today in the American Journal of Clinical Pathology demonstrated the ability ... more

February 23, 2011
Xeloda approved in Japan for Additional Indication of Advanced or Recurrent Gastric Cancer, which is Not Amenable to Curative Resection
Dear Investor, Please find attached a press release by Chugai: http://www.roche.com/inv-update-2011-02-23-annex.pdf Do not ... more

February 16, 2011
Roche initiates phase III study investigating infusion-free administration of MabThera for patients with non-Hodgkin's lymphoma
Roche today announced the initiation of a phase III study to investigate a subcutaneous formulation of MabThera (rituximab) ... more

February 14, 2011
Lucentis Phase III study meets primary endpoint for improving vision in patients with diabetic macular edema (DME)
Roche today announced that one of two Phase III studies evaluating monthly Lucentis (ranibizumab injection) in patients with ... more

February 08, 2011
Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer
Roche announced today that OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (carboplatin ... more

February 02, 2011
Full reconciliation of Chugai 2010 results into IFRS
Following the publication of Chugai's official 2010 results, Roche offers this investor update which reconciles these ... more

February 02, 2011
Solid overall results
Mid-single digit sales growth in local currencies excluding Tamiflu - Strong profit growth - Promising late stage pharmaceutical ... more

January 31, 2011
FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) as a maintenance ... more

January 28, 2011
Early successful readout of Tarceva study in a distinct form of lung cancer
Roche today announced that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped ... more

January 19, 2011
Reminder: Invitation to Roche's Full Year Results for 2010
Roche will publish its Full Year Results for 2010 prior to the opening of the Swiss Stock Exchange on 2 February at 7:00 CET ... more

January 19, 2011
Roche personalized investigational medicine shows survival benefit in advanced skin cancer
Roche today announced that BRIM3, a Phase III clinical study of RG7204 (PLX4032), met its co-primary endpoints showing a significant ... more

January 17, 2011
Changes to the Roche Corporate Executive Committee
Erich Hunziker (born 1953), Chief Financial Officer, Chief Information Officer and Deputy Head of the Corporate Executive ... more

January 05, 2011
FDA grants supplemental approval for ACTEMRA
Roche today announced that the United States Food and Drug Administration has extended the ACTEMRA label to include inhibition ... more

January 04, 2011
Roche's Full Year Results for 2010
Roche will publish its Full Year Results for 2010 prior to the opening of the Swiss Stock Exchange on 2 February at 7:00 CET ... more